Navigation Links
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Date:8/19/2007

g statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to fluctuations in our stock price, as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of the Company's most recent Quarterly Report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward- looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.

Quark Pharmaceuticals, Inc The Ruth Group

Gavin Samuels Stephanie Carrington / Elizabeth

SVP, Business Development Scott (investors)

(646) 502-7488 (646) 536-7017 / 7014

scarrington@theruthgroup.com

escott@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, today ... 28, 2015. Net sales for the first ... 1.4% compared with the first quarter of 2014.  This ... 6.0% decline related to foreign currency exchange.  In local ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17
... overall survival rate from,cancer now is lower in older ... in part because of a lack of access to ... a study by pediatric,oncologists at Children,s Hospital of Pittsburgh ... than 15 with cancer have,improved dramatically over the last ...
... Period -, EXTON, Pa., Jan. 15 ... been completed in the pivotal,Phase III multi-center, double-blind, ... the treatment of,nasolabial folds, or wrinkles (Studies IT-A-005 ... of the study., Isolagen also announced the ...
Cached Medicine Technology:Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Morganville, NJ (PRWEB) May 04, 2015 ... that he has been chosen to receive the America’s ... Board. Dr. Champagne’s selection as a top dentist ... his commitment to continuing education and his compassion for ... Board selects professionals who exemplify excellence in their field. ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... The Accreditation for Cardiovascular ... congenital heart disease (CHD) standards for Pediatric ... Driven by the latest available clinical evidence, ... of interventional procedures in pediatric patients and ... ACE CHD Standards for PCCL Accreditation, like ...
(Date:5/4/2015)... May 04, 2015 Sara Soulati, CEO ... practice management firm in Los Angeles associated with the ... patent-pending status of The Sara Soulati Health For Life ... 2010, is a lifestyle modification and disease prevention program. ... to the U. S. Patents and Trademarks Office and ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... are a valuable tool for controlling infectious diseases ... Routine immunizations and supplemental immunization activities, such as ... to entire populations. Current measurements used to determine ... flawed and inconsistent. According to a new study ...
... announces a partnership with the U.S. Food and Drug ... Center of Excellence in Regulatory Science and Innovation (CERSI). ... an initial $1 million grant, which is potentially part ... and manufacturing. Experts in science, medicine ...
... more rapid innovation in science and technology, Peter Thiel ... Breakout Labs. Speaking at Stanford to an event ... Thiel announced that Breakout Labs will use a revolving ... research is funded by helping independent scientists and early-stage ...
... building blocks of proteins, are essential to support the ... An insufficient supply of amino acids in the mother,s ... developmental abnormalities and complications of pregnancy that result in ... cutting-edge article in the peer-reviewed journal Cellular Reprogramming ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... New research has the potential to revolutionize the treatment ... a million Canadians which is expected to strike even more ... AF is the most common type of heart arrhythmia ... greater risk for stroke. Now, there is a new drug ...
Cached Medicine News:Health News:Researchers develop method to better estimate vaccine coverage 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 3Health News:Peter Thiel announces Breakout Labs to energize innovation 2Health News:Inadequate supply of protein building blocks may explain pregnancy failures in bovine cloning experiments 2Health News:Larger Food Portions May Be Seen as Status Symbols 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: